Race and Medicine: Framing [Is] the Problem
This introductory chapter explores the intersections of race, science, law, and commerce and shows how a larger scheme of institutional, legal, and commercial imperatives is shaping the use of race in biomedicine. The drug BiDil is used as an entry point into this study. BiDil is a combination of two generic drugs used to dilate blood vessels—hence “Bi” (two) and “Dil” (dilators). Its development into a racialized drug is worth taking into account—this study does so by unearthing five themes in BiDil's history and the overall issue of racialized medicine: the institutional mandates that promote the introduction of race into biomedical research and practice.
Columbia Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us .